BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S, Geboes K, Peeters M. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012;106:1926-33. [PMID: 22596235 DOI: 10.1038/bjc.2012.184] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018;2018:2397863. [PMID: 30008744 DOI: 10.1155/2018/2397863] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
2 Zhu J, Zhang F, Zhou J, Li H. Assessment of therapeutic response in Crohn's disease using quantitative dynamic contrast enhanced MRI (DCE-MRI) parameters: A preliminary study. Medicine (Baltimore) 2017;96:e7759. [PMID: 28796069 DOI: 10.1097/MD.0000000000007759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
3 O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016;130:495-503. [PMID: 27576699 DOI: 10.1007/s11060-016-2243-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
4 Van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, Seufferlein T. Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers (Basel). 2016;8. [PMID: 27589804 DOI: 10.3390/cancers8090081] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
5 Xu L, Ge X, Sun N, Liu X. Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy. Acta Radiol 2020;61:1316-25. [PMID: 32053003 DOI: 10.1177/0284185120903139] [Reference Citation Analysis]
6 Fukami Y, Kurumiya Y, Kobayashi S. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): an analysis of tumor activity. Updates Surg. 2014;66:223-225. [PMID: 24864037 DOI: 10.1007/s13304-014-0256-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
7 Niccoli Asabella A, Di Palo A, Altini C, Ferrari C, Rubini G. Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives. Int J Mol Sci 2017;18:E1864. [PMID: 28846661 DOI: 10.3390/ijms18091864] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
8 Heijmen L, ter Voert EE, Oyen WJ, Punt CJ, van Spronsen DJ, Heerschap A, de Geus-Oei LF, van Laarhoven HW. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer. PLoS One. 2015;10:e0120823. [PMID: 25831053 DOI: 10.1371/journal.pone.0120823] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
9 Saha A, Peck KK, Lis E, Holodny AI, Yamada Y, Karimi S. Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications. Spine (Phila Pa 1976) 2014;39:E1433-40. [PMID: 25188594 DOI: 10.1097/BRS.0000000000000570] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
10 Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol 2014;49:46-56. [PMID: 23525980 DOI: 10.1007/s00535-013-0790-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kim YE, Joo B, Park MS, Shin SJ, Ahn JB, Kim MJ. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. Cancer Res Treat. 2016;48:1210-1221. [PMID: 26987390 DOI: 10.4143/crt.2015.374] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
12 Mross K, Büchert M, Frost A, Medinger M, Stopfer P, Studeny M, Kaiser R. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer 2014;14:510. [PMID: 25012508 DOI: 10.1186/1471-2407-14-510] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ellmann S, Seyler L, Evers J, Heinen H, Bozec A, Prante O, Kuwert T, Uder M, Bäuerle T. Prediction of early metastatic disease in experimental breast cancer bone metastasis by combining PET/CT and MRI parameters to a Model-Averaged Neural Network. Bone 2019;120:254-61. [PMID: 30445200 DOI: 10.1016/j.bone.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Uutela A, Ovissi A, Hakkarainen A, Ristimäki A, Lundbom N, Kallio R, Soveri LM, Salminen T, Ålgars A, Halonen P, Ristamäki R, Nordin A, Blanco Sequeiros R, Rinta-Kiikka I, Lantto E, Virtanen J, Pääkkö E, Liukkonen E, Saunavaara J, Ryymin P, Lammentausta E, Osterlund P, Isoniemi H; RAXO Study Group. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial). ESMO Open 2021;6:100208. [PMID: 34325107 DOI: 10.1016/j.esmoop.2021.100208] [Reference Citation Analysis]
15 Colloca G, Venturino A, Guarneri D. Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer. Clinical Oncology 2016;28:e155-64. [DOI: 10.1016/j.clon.2016.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Russo V, Di Paola L. Chemical reaction engineering methodologies for post-contrastographic biomedical imaging analysis: METHODOLOGIES FOR POST-CONTRASTOGRAPHIC ANALYSIS. Asia-Pac J Chem Eng 2014;9:354-63. [DOI: 10.1002/apj.1803] [Reference Citation Analysis]
17 Nielsen K, Scheffer HJ, Volders JH, van der Vorst MJ, van Tilborg AA, Comans EF, de Lange-de Klerk ES, Sietses C, Meijer S, Meijerink MR, van den Tol MP. Radiofrequency Ablation to Improve Survival After Conversion Chemotherapy for Colorectal Liver Metastases. World J Surg 2016;40:1951-8. [PMID: 27220509 DOI: 10.1007/s00268-016-3554-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Mainenti PP, Romano F, Pizzuti L, Segreto S, Storto G, Mannelli L, Imbriaco M, Camera L, Maurea S. Non-invasive diagnostic imaging of colorectal liver metastases. World J Radiol 2015; 7(7): 157-169 [PMID: 26217455 DOI: 10.4329/wjr.v7.i7.157] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
19 Jerome NP, Papoutsaki MV, Orton MR, Parkes HG, Winfield JM, Boss MA, Leach MO, deSouza NM, Collins DJ. Development of a temperature-controlled phantom for magnetic resonance quality assurance of diffusion, dynamic, and relaxometry measurements. Med Phys 2016;43:2998-3007. [PMID: 27277048 DOI: 10.1118/1.4948997] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
20 De Robertis R, Tinazzi Martini P, Demozzi E, Puntel G, Ortolani S, Cingarlini S, Ruzzenente A, Guglielmi A, Tortora G, Bassi C, Pederzoli P, D’Onofrio M. Prognostication and response assessment in liver and pancreatic tumors: The new imaging. World J Gastroenterol 2015; 21(22): 6794-6808 [PMID: 26078555 DOI: 10.3748/wjg.v21.i22.6794] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
21 Marien KM, Croons V, Martinet W, De Loof H, Ung C, Waelput W, Scherer SJ, Kockx MM, De Meyer GR. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update. Expert Rev Mol Diagn 2015;15:399-414. [PMID: 25585649 DOI: 10.1586/14737159.2015.993972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chiaradia M, Baranes L, Van Nhieu JT, Vignaud A, Laurent A, Decaens T, Charles-Nelson A, Brugières P, Katsahian S, Djabbari M, Deux JF, Sobhani I, Karoui M, Rahmouni A, Luciani A. Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis? J Magn Reson Imaging 2014;39:317-25. [PMID: 23723012 DOI: 10.1002/jmri.24172] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
23 McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med 2015;7:368-79. [PMID: 25700172 DOI: 10.15252/emmm.201404271] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 14.9] [Reference Citation Analysis]
24 Matos AP, Velloni F, Ramalho M, AlObaidy M, Rajapaksha A, Semelka RC. Focal liver lesions: Practical magnetic resonance imaging approach. World J Hepatol 2015; 7(16): 1987-2008 [PMID: 26261689 DOI: 10.4254/wjh.v7.i16.1987] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
25 Cheung HMC, Karanicolas PJ, Hsieh E, Coburn N, Maraj T, Kim JK, Elhakim H, Haider MA, Law C, Milot L. Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomy. Eur Radiol 2018;28:3505-12. [PMID: 29476216 DOI: 10.1007/s00330-018-5331-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
26 Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. J Hepatol. 2015;62:690-700. [PMID: 25457198 DOI: 10.1016/j.jhep.2014.10.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
27 Chen J, Yin HB. Dynamic contrast-enhanced magnetic resonance imaging of the liver: Applications in treatment of hepatic malignancies with vascular targeting agents. Shijie Huaren Xiaohua Zazhi 2014; 22(32): 4928-4933 [DOI: 10.11569/wcjd.v22.i32.4928] [Reference Citation Analysis]
28 Miyazaki K, Jerome NP, Collins DJ, Orton MR, d'Arcy JA, Wallace T, Moreno L, Pearson AD, Marshall LV, Carceller F, Leach MO, Zacharoulis S, Koh DM. Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. Eur Radiol 2015;25:2641-50. [PMID: 25773937 DOI: 10.1007/s00330-015-3666-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
29 Ueda S, Saeki T. Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy. Breast Cancer 2014;21:776-9. [PMID: 24795075 DOI: 10.1007/s12282-014-0534-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Lawler M, Johnston B, Van Schaeybroeck S, Salto-tellez M, Wilson R, Dunlop M, Johnston PG. Colorectal Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1219-1280.e15. [DOI: 10.1016/b978-0-323-47674-4.00074-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Goh V, Gourtsoyianni S, Koh DM. Functional imaging of the liver. Semin Ultrasound CT MR. 2013;34:54-65. [PMID: 23395318 DOI: 10.1053/j.sult.2012.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
32 Thng CH, Koh TS, Collins D, Koh DM. Perfusion imaging in liver MRI. Magn Reson Imaging Clin N Am 2014;22:417-32. [PMID: 25086937 DOI: 10.1016/j.mric.2014.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mainenti PP, Stanzione A, Guarino S, Romeo V, Ugga L, Romano F, Storto G, Maurea S, Brunetti A. Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging. World J Gastroenterol 2019; 25(35): 5233-5256 [PMID: 31558870 DOI: 10.3748/wjg.v25.i35.5233] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
34 Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA. PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 2015;14:35-40. [PMID: 25481195 DOI: 10.1016/j.clcc.2014.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
35 Wang C, Subashi E, Liang X, Yin FF, Chang Z. Evaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison study. Phys Med Biol 2016;61:4763-80. [PMID: 27272391 DOI: 10.1088/0031-9155/61/13/4763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Krishan S, Patel A, Sud R, Puri R, Vaid A, Lipi L, Kataria T. Rectal perfusion parameters normalised to tumour-free rectal wall can predict response to neoadjuvant chemoradiotherapy. Clin Radiol. 2018;73:151-157. [PMID: 29102233 DOI: 10.1016/j.crad.2017.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
37 Banerji U, Workman P. Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology 2016;43:436-45. [DOI: 10.1053/j.seminoncol.2016.06.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
38 Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol 2015;17:1007-15. [PMID: 25665807 DOI: 10.1093/neuonc/nov019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
39 Rodríguez-Fraile M, Cózar-Santiago MP, Sabaté-Llobera A, Caresia-Aróztegui AP, Delgado Bolton RC, Orcajo-Rincon J, de Arcocha-Torres M, García-Velloso MJ, García-Talavera P. FDG PET/CT in colorectal cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020;39:57-66. [PMID: 31776063 DOI: 10.1016/j.remn.2019.09.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Van Schaeybroeck S, Lawler M, Johnston B, Salto-tellez M, Lee J, Loughlin P, Wilson R, Johnston PG. Colorectal Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1278-1335.e14. [DOI: 10.1016/b978-1-4557-2865-7.00077-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Creasy JM, Midya A, Chakraborty J, Adams LB, Gomes C, Gonen M, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI, Do RKG, Simpson AL. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. Eur Radiol 2019;29:458-67. [PMID: 29922934 DOI: 10.1007/s00330-018-5542-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Yang JF, Zhao ZH, Zhang Y, Zhao L, Yang LM, Zhang MM, Wang BY, Wang T, Lu BC. Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma. World J Gastroenterol 2016; 22(13): 3652-3662 [PMID: 27053857 DOI: 10.3748/wjg.v22.i13.3652] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
43 Granata V, Fusco R, Avallone A, Catalano O, Piccirillo M, Palaia R, Nasti G, Petrillo A, Izzo F. A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases. Future Oncol 2018;14:2189-206. [PMID: 30084273 DOI: 10.2217/fon-2018-0080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
44 Bijlstra OD, Boreel MME, van Mossel S, Burgmans MC, Kapiteijn EHW, Oprea-lager DE, Rietbergen DDD, van Velden FHP, Vahrmeijer AL, Swijnenburg R, Mieog JSD, de Geus-oei L. The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics 2022;12:715. [DOI: 10.3390/diagnostics12030715] [Reference Citation Analysis]
45 Rahmim A, Bak-Fredslund KP, Ashrafinia S, Lu L, Schmidtlein CR, Subramaniam RM, Morsing A, Keiding S, Horsager J, Munk OL. Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features. Eur J Radiol 2019;113:101-9. [PMID: 30927933 DOI: 10.1016/j.ejrad.2019.02.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
46 Beckers RC, Lambregts DM, Lahaye MJ, Rao S, Kleinen K, Grootscholten C, Beets GL, Beets-tan RG, Maas M. Advanced imaging to predict response to chemotherapy in colorectal liver metastases – a systematic review. HPB 2018;20:120-7. [DOI: 10.1016/j.hpb.2017.10.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
47 Yuan SJ, Qiao TK, Qiang JW, Cai SQ, Li RK. The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas. J Ovarian Res 2017;10:65. [PMID: 28950890 DOI: 10.1186/s13048-017-0362-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tampellini M, Gned D, Baratelli C, Brizzi MP, Ottone A, Alabiso I, Bertaggia C, Di Maio M, Scagliotti GV, Veltri A. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy. Radiol Med 2016;121:950-7. [PMID: 27601143 DOI: 10.1007/s11547-016-0685-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Lu H, Wu Y, Liu X, Huang H, Jiang H, Zhu C, Man Y, Liu P, Li X, Chen Z, Long X, Pang Q, Deng S, Gu J. The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy. Cancer Manag Res 2021;13:6065-78. [PMID: 34377025 DOI: 10.2147/CMAR.S314289] [Reference Citation Analysis]
50 Kim SH, Lee JM, Gupta SN, Han JK, Choi BI. Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. J Magn Reson Imaging. 2014;40:730-737. [PMID: 24307571 DOI: 10.1002/jmri.24387] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
51 Braunagel M, Graser A, Reiser M, Notohamiprodjo M. The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World J Urol 2014;32:47-58. [PMID: 23588813 DOI: 10.1007/s00345-013-1074-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
52 Cannella R, Sartoris R, Grégory J, Garzelli L, Vilgrain V, Ronot M, Dioguardi Burgio M. Quantitative magnetic resonance imaging for focal liver lesions: bridging the gap between research and clinical practice. Br J Radiol 2021;94:20210220. [PMID: 33989042 DOI: 10.1259/bjr.20210220] [Reference Citation Analysis]
53 O'Neill H, Malik V, Johnston C, Reynolds JV, O'Sullivan J. Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles? Pharmaceuticals (Basel) 2019;12:E16. [PMID: 30678034 DOI: 10.3390/ph12010016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
54 Liang HY, Huang YQ, Yang ZX, Ying-Ding MS, Rao SX. Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. Eur Radiol. 2016;26:2009-2018. [PMID: 26494642 DOI: 10.1007/s00330-015-4043-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
55 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
56 Ye L, Wei Y, Zhu D, Chen T, Xu J. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab: Tumor shrinkage in colorectal cancer. J Gastroenterol Hepatol 2015;30:674-9. [DOI: 10.1111/jgh.12847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
57 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
58 Ravanelli M, Agazzi GM, Tononcelli E, Roca E, Cabassa P, Baiocchi G, Berruti A, Maroldi R, Farina D. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. Radiol med 2019;124:877-86. [DOI: 10.1007/s11547-019-01046-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
59 Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med. 2013;54:2062-2069. [PMID: 24136935 DOI: 10.2967/jnumed.113.119909] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
60 Jin T, Iordanova B, Hitchens TK, Modo M, Wang P, Mehrens H, Kim SG. Chemical exchange-sensitive spin-lock (CESL) MRI of glucose and analogs in brain tumors. Magn Reson Med 2018;80:488-95. [PMID: 29569739 DOI: 10.1002/mrm.27183] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
61 Dunet V, Halkic N, Prior JO, Anaye A, Meuli RA, Sempoux C, Denys A, Schmidt S. Detection and Viability of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Multiparametric PET/CT-MRI Study. Clin Nucl Med. 2017;42:258-263. [PMID: 28166142 DOI: 10.1097/rlu.0000000000001538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
62 Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D’Angelica MI, DeMatteo RP, Klimstra DS. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21:2675-2683. [PMID: 24664624 DOI: 10.1245/s10434-014-3649-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
63 Sandrasegaran K. Functional MR imaging of the abdomen. Radiol Clin North Am. 2014;52:883-903. [PMID: 24889176 DOI: 10.1016/j.rcl.2014.02.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
64 Maclean D, Tsakok M, Gleeson F, Breen DJ, Goldin R, Primrose J, Harris A, Franklin J. Comprehensive Imaging Characterization of Colorectal Liver Metastases. Front Oncol 2021;11:730854. [PMID: 34950575 DOI: 10.3389/fonc.2021.730854] [Reference Citation Analysis]
65 Rodríguez-fraile M, Cózar-santiago M, Sabaté-llobera A, Caresia-aróztegui A, Delgado-bolton R, Orcajo-rincon J, de Arcocha-torres M, García-velloso M, García-talavera P. FDG PET/CT in colorectal cancer. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2020;39:57-66. [DOI: 10.1016/j.remnie.2019.12.001] [Reference Citation Analysis]
66 Engelmann BE, Loft A, Kjær A, Nielsen HJ, Gerds TA, Benzon EV, Brünner N, Christensen IJ, Hansson SH, Holländer NH, Kristensen MH, Löfgren J, Markova E, Sloth C, Højgaard L. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist 2014;19:164-72. [PMID: 24451199 DOI: 10.1634/theoncologist.2013-0229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
67 Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg. 2014;259:861-872. [PMID: 24509207 DOI: 10.1097/sla.0000000000000525] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 5.1] [Reference Citation Analysis]
68 Wang C, Subashi E, Yin FF, Chang Z. Dynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI. Med Phys 2016;43:1335-47. [PMID: 26936718 DOI: 10.1118/1.4941739] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
69 Florea A, Mottaghy FM, Bauwens M. Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status. Int J Mol Sci 2021;22:5544. [PMID: 34073992 DOI: 10.3390/ijms22115544] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Rossanese O, Eccles S, Springer C, Swain A, Raynaud FI, Workman P, Kirkin V. The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. Drug Discovery Today: Disease Models 2016;21:23-32. [DOI: 10.1016/j.ddmod.2017.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Baker JH, McPhee KC, Moosvi F, Saatchi K, Häfeli UO, Minchinton AI, Reinsberg SA. Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF). Contrast Media Mol Imaging 2016;11:77-88. [PMID: 26268906 DOI: 10.1002/cmmi.1661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
72 Baik H, Lee SM, Seo SH, An MS, Kim KH, Bae KB, Oh MK, Hong KH. Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer. ANZ J Surg 2018;88:587-91. [PMID: 28687025 DOI: 10.1111/ans.14098] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Xia Q, Liu J, Wu C, Song S, Tong L, Huang G, Feng Y, Jiang Y, Liu Y, Yin T, Ni Y. Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging. 2015;15:19. [PMID: 26589835 DOI: 10.1186/s40644-015-0055-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
74 Dujardin PA, Léger J, Lecomte T, Patat F, Chassagnon G, Bleuzen A. Perfusion Quantification of Liver Metastases of Colorectal Cancer Treated with Anti-angiogenic-Based Therapy: Assessment of Intra- and Inter-observer Reproducibility of Parameters in Three Regions of Interest Outlining Lesions. Ultrasound Med Biol 2020;46:286-96. [PMID: 31753600 DOI: 10.1016/j.ultrasmedbio.2019.10.011] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Lim Y, Bang JI, Han SW, Paeng JC, Lee KH, Kim JH, Kang GH, Jeong SY, Park KJ, Kim TY. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. Eur J Nucl Med Mol Imaging 2017;44:757-64. [PMID: 27888325 DOI: 10.1007/s00259-016-3577-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
76 van Helden EJ, Hoekstra OS, Boellaard R, Roth C, Mulder ER, Verheul HM, Menke-van der Houven van Oordt CW. Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS One 2016;11:e0155178. [PMID: 27196139 DOI: 10.1371/journal.pone.0155178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
77 Tirumani SH, Kim KW, Nishino M, Howard SA, Krajewski KM, Jagannathan JP, Cleary JM, Ramaiya NH, Shinagare AB. Update on the role of imaging in management of metastatic colorectal cancer. Radiographics. 2014;34:1908-1928. [PMID: 25384292 DOI: 10.1148/rg.347130090] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
78 Barnes SL, Whisenant JG, Loveless ME, Yankeelov TE. Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics. 2012;4:442-478. [PMID: 23105959 DOI: 10.3390/pharmaceutics4030442] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]